Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0718 in Adults and Adolescents With Asthma
NCT06488755Phase 3Active, not recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing SIM0718 injection with Placebo (2 arms). Primary endpoint: Annualized rate of severe asthma exacerbation events at 52 weeks. Started Jun 2024; status: active, not recruiting.
02
Drugs
rademikibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06488755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488755.